Ocuphire Pharma
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-02-01
- Employees
- 14
- Market Cap
- $31.9M
- Website
- http://www.ocuphire.com
- Introduction
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia
- Conditions
- Presbyopia
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 545
- Registration Number
- NCT06542497
- Locations
- 🇺🇸
United States, San Antonio, Texas, United States
Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances
- Conditions
- Mesopic VisionNight Vision Loss
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT06349759
- Locations
- 🇺🇸
United States Phoenix, Phoenix, Arizona, United States
🇺🇸United States Scottsdale, Scottsdale, Arizona, United States
🇺🇸United States, Tampa, Florida, United States
Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia
- Conditions
- Presbyopia
- Interventions
- Other: PlaceboOther: Low dose pilocarpine vehicle
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 333
- Registration Number
- NCT05646719
- Locations
- 🇺🇸
Phoenix, AZ, Phoenix, Arizona, United States
🇺🇸Azusa, CA, Azusa, California, United States
🇺🇸Newport Beach, CA, Newport Beach, California, United States
Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
- Conditions
- MydriasisDilation
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT05223478
- Locations
- 🇺🇸
Clinical Site 1, Longwood, Florida, United States
🇺🇸Clinical Site 2, Athens, Ohio, United States
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
- Conditions
- MydriasisDilation
- Interventions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Ocuphire Pharma, Inc.
- Target Recruit Count
- 368
- Registration Number
- NCT05134974
- Locations
- 🇺🇸
Clinical Site 10, Newport Beach, California, United States
🇺🇸Clinical Site 12, Westminster, California, United States
🇺🇸Clinical Site 9, Delray Beach, Florida, United States
- Prev
- 1
- 2
- 3
- Next
News
Advancements in Clinical Trials for Fabry Disease, C. difficile Infections, and Mydriasis
• Clinical trials are actively progressing for Fabry Disease, with companies like Idorsia and Sanofi Genzyme developing novel therapies. • Emerging treatments like Venglustat and Pegunigalsidase alfa are expected to significantly impact the Fabry Disease market in the coming years. • Research and development efforts are also focused on Clostridium Difficile Infections, with Vedanta Biosciences leading Phase 3 trials for VE303. • Mydriasis treatments are advancing, with companies like Eyenovia exploring solutions like MYDCOMBI for pupil dilation.
Ocuphire Pharma Acquires Opus Genetics, Expanding Gene Therapy Pipeline for Inherited Retinal Diseases
Ocuphire Pharma has acquired Opus Genetics in an all-stock transaction, with the combined company renamed Opus Genetics, Inc., focusing on inherited retinal diseases.
Phentolamine Ophthalmic Solution (Ryzumvi) Demonstrates Efficacy in Reversing Mydriasis in Phase 3 Trials
Phentolamine ophthalmic solution 0.75% (Ryzumvi) significantly reversed pharmacologically-induced mydriasis in MIRA-2 and MIRA-3 Phase 3 trials.
Ocuphire Pharma Initiates Phase 3 Trial of Phentolamine Ophthalmic Solution for Presbyopia
Ocuphire Pharma has dosed the first patient in its Phase 3 VEGA-3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia.
Ocuphire Pharma Initiates Phase 3 VEGA-3 Trial of Phentolamine Ophthalmic Solution for Presbyopia
Ocuphire Pharma has dosed the first patient in its Phase 3 VEGA-3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia.